We report here for the first time that Yes is overexpressed in breast cancer cells with acquired resistance to T-DM1 owing to amplification of chromosome region 18p11.32, and showed that this increase in Yes expression conferred resistance to different types of HER2-targeted drugs. Here, ERBB2 is linked to breast carcinoma.